Options for Treating Relapsed/Refractory Follicular Lymphoma
April 03, 2020 04:54pm
By Sonali M. Smith, MD
Victor A. Chow, MD, discusses the next steps for chimeric antigen receptor T-cell therapy in patients with B-cell lymphomas.
Victor A. Chow, MD, a senior hematology/oncology fellow at the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discussed the next steps for chimeric antigen receptor (CAR) T-cell therapy in patients with B-cell lymphomas.
The use of CAR T cells has been exciting in the field. Chow says this excitement has led to a lot of research and money investigating its potential in various settings. While CAR T cells have been approved for treatment of individuals after 2 or more lines of therapy, studies are now looking at moving this to the upfront setting.
Prospective trials comparing CAR T cells to autologous stem cell transplant will help determine which treatment a relapsed patient should receive. Chow expects to have a better understanding from these data in the next year or so.
See more fromthis study